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Latent reservoirs of HIV-1-infected cells are refrac-
tory to antiretroviral therapies (ART) and remain the
major barrier to curing HIV-1. Because latently in-
fected cells are long-lived, immunologically invisible,
and may undergo homeostatic proliferation, a
‘‘shock and kill’’ approach has been proposed to
eradicate this reservoir by combining ART with in-
ducers of viral transcription. However, all attempts
to alter the HIV-1 reservoir in vivo have failed to
date. Using humanized mice, we show that broadly
neutralizing antibodies (bNAbs) can interfere with
establishment of a silent reservoir by Fc-FcR-medi-
ated mechanisms. In established infection, bNAbs
or bNAbs plus single inducers are ineffective in
preventing viral rebound. However, bNAbs plus a
combination of inducers that act by independent
mechanisms synergize to decrease the reservoir as
measured by viral rebound. Thus, combinations of
inducers and bNAbs constitute a therapeutic strat-
egy that impacts the establishment andmaintenance
of the HIV-1 reservoir in humanized mice.
INTRODUCTION
HIV-1 infection can be suppressed with combination antiretro-
viral therapy (ART). However, therapy must be maintained for
the life of the individual because even years of ART does not
eliminate a reservoir of latently infected cells harboring replica-
tion-competent provirus (Siliciano et al., 2003). As a result,
ART interruption produces rapid viral rebound (Davey et al.,
1999). One strategy proposed to eliminate latent viruses involves
reversing their latent state using agents that induce HIV-1 RNA
synthesis under the cover of ART (Deeks, 2012). However, allattempts to alter the reservoir by intensifying ART with additional
antiretroviral drugs (Dinoso et al., 2009; Gandhi et al., 2010) or by
administering viral inducers in the presence of ART have failed to
date (Archin et al., 2014; Dybul et al., 2002; Lafeuillade et al.,
2001; Prins et al., 1999).
Like ART, broadly neutralizing antibodies (bNAbs) against HIV-
1 can completely suppress viremia in HIV-1-infected humanized
mice (hu-mice) (Horwitz et al., 2013; Klein et al., 2012b) and
SHIV-infected macaques (Barouch et al., 2013; Shingai et al.,
2013). Although the composition of the reservoir is ill defined
andmay differ between ART and antibody treatments, discontin-
uation of ART or bNAb therapy in hu-mice and macaques results
in viral rebound, indicating persistence of a functionally silent
pool of cells harboring replication-competent virus. Moreover,
the relative frequency of latently infected CD4+ T cells as
measured by ex vivo reactivation is similar in ART-suppressed
hu-mice and humans (Chun et al., 1997; Denton et al., 2012; Finzi
et al., 1997; Marsden et al., 2012; Wong et al., 1997). Thus, anti-
bodies and ART control HIV-1 infection in hu-mice but allow
persistence of a latent reservoir.
Unlike ART, however, antibodies can engage the host immune
system by virtue of their Fc effector domains (Nimmerjahn and
Ravetch, 2008) and thereby accelerate clearance of cell-free
virus (Igarashi et al., 1999), induce antibody-dependent cytotox-
icity to kill infected cells (Bonsignori et al., 2012; Chung et al.,
2011; Forthal et al., 2013; Forthal et al., 2001; Jost and Altfeld,
2013; Sun et al., 2011), and produce immune complexes that
activate dendritic cells to become potent antigen-presenting
cells (Dhodapkar et al., 2005). Finally, some classes of bNAbs
can prevent cell-cell transmission of HIV-1(Abela et al., 2012;
Malbec et al., 2013), whereas ART’s activity in this regard is still
debated (Agosto et al., 2014; Schiffner et al., 2013; Sigal et al.,
2011).
Here, we examine the effects of bNAbs on the establishment
of the reservoir and on its maintenance in the presence of
inducers of viral transcription by measuring viral rebound. We
find that bNAbs can interfere with the establishment of theCell 158, 989–999, August 28, 2014 ª2014 Elsevier Inc. 989
reservoir by a mechanism that depends on their ability to bind to
Fc receptors and that bNAbs plus a combination of inducers can
reduce viral rebound from the reservoir in established infections
in hu-mice.
RESULTS
Postexposure Prophylaxis with bNAbs
The ART-resistant reservoir is established early in infection, as
evidenced by postexposure prophylaxis experiments in humans
and macaques (Landovitz and Curry, 2009; Lifson et al., 2000;
Tsai et al., 1998; Tsai et al., 1995; Whitney et al., 2014). Postex-
posure prophylaxis with ART or previous-generation bNAbs is
only effective when administered within 24 hr of intravenous
exposure (Ferrantelli et al., 2007; Landovitz and Curry, 2009;
Lifson et al., 2000; Nishimura et al., 2003; Tsai et al., 1995,
1998). To determine whether the current generation of more
potent bNAbs can abort the establishment of a latent HIV-1
reservoir at later time points, we performed postexposure pro-
phylaxis experiments in hu-mice (Figure 1A). Mice were infected
with HIV-1YU2 (150 ng p24) by intraperitoneal injection and were
treated with either ART (raltegravir, emtricitabine, tenofovir)
(Denton et al., 2012; Nischang et al., 2012) or a tri-mix of bNAbs
(3BNC117, 10-1074, and PG16) (Horwitz et al., 2013) 4 or 8 days
after infection, when viremia was already detectable in 51 of 70
mice. Plasma viremia varied from undetectable to 2.70 3 106
viral RNA copies/ml at 4 days after infection (Figures 1B–1E
and Data S1 available online). In the absence of therapy, 14
out of 15 mice in the control group developed sustained plasma
viremia, ranging from 2.48 3 103 to 4.19 3 106 copies/ml
(Figure 1B).
Doses of ART and antibodies were chosen on the basis of their
therapeutic efficacy in chronic HIV-1 infection in hu-mice (Den-
ton et al., 2012; Horwitz et al., 2013; Klein et al., 2012b; Nischang
et al., 2012). ART was administered in the food for up to 40 days,
starting 4 days after infection (Denton et al., 2012; Nischang
et al., 2012). Antibodies were administered subcutaneously
with a loading dose of 3 mg per mouse and three to five subse-
quent doses of 1.5 mg each, spaced 3–4 days apart (Figure 1A).
Consistent with human and macaque studies, 18 of 22 mice
treated with ART showed viremia after ART termination, demon-
strating that this form of therapy is relatively ineffective at pre-
venting reservoir development in hu-mice when administered
4 days after infection (Figure 1C). Among the 18 viremic mice,
viremia was first detected 28–84 days after ART termination (Fig-
ures 1C and S1). In contrast, 10 of 21 hu-mice treated with anti-
bodies 4 days after infection showed viremia by the terminal
point (p = 0.027, Figure 1F), and for 9 of these 10 viremic mice,
the first detectable viremia occurred 74–107 days after the last
antibody injection (Figures 1D and S1 and Data S1A). The delay
in viral rebound observed for mice treated with antibody at day 4
was statistically significant compared to ART-treated mice (Fig-
ure S1). The mice that rebounded showed a geometric mean
antibody concentration at rebound of 0.46 mg/ml. However,
sustained inhibitory antibody levels did not account for the 11
mice that did not rebound, all of which had antibody levels %
0.50 mg/ml by termination (Data S1C). In contrast to bNAb treat-
ment at day 4, bNAb treatment after 8 days was far less effective,990 Cell 158, 989–999, August 28, 2014 ª2014 Elsevier Inc.resulting in viremia in 10 of the 11 treated mice 44–58 days after
the last antibody injection (Figures 1E and 1F and Data S1B).
Mice in the early treatment group that failed to show detect-
able plasma viremia were further examined for the presence of
human CD4+ T cells and cell-associated HIV-1 RNA and DNA
in the spleen.We found thatmice that failed to develop sustained
plasma viremia had similar percentages ofCD4+ T cells relative to
infected controls, which correlated with absolute CD4+ T cell
levels (Figures 1G and S2). Therefore, differences in CD4+
T cell levels are unlikely to account for the observed differences
between viremic and aviremic mice (Figure 1G). Moreover,
T-cell-associated HIV-1 RNA levels were consistent with plasma
viral loads, with mice that remained aviremic having either unde-
tectable or lower cell-associated HIV-1 RNA than mice that
developed sustained viremia (Figure 1H).
Wemeasured cell-associated viral DNA as an imperfect surro-
gate of the HIV-1 reservoir. HIV-1 DNA is thought to overestimate
the reservoir because it fails to exclude damaged or incomplete
viral sequences that cannot be reactivated (Ho et al., 2013). In
addition, the overall number of cells assayed in mice is limited
and therefore the assay is not very sensitive. Nevertheless, we
found HIV-1 DNA measurements to be consistent with each
mouse’s rebound status (Figure 1I). We conclude that bNAbs
can interfere with the establishment of the latent HIV-1 reservoir
in hu-mice, as determined by the significant delay in viral
rebound.
Fc Receptor Binding Is Required for bNAb Activity
To determine whether the efficacy of bNAbs is dependent on
the antibodies’ ability to engage components of the immune
system through their Fc domains, we repeated the day 4 post-
exposure prophylaxis experiments using the same tri-mix of
bNAbs carrying Fc region mutations that abrogate both human
and mouse Fc-receptor binding (G236R/L328R; GRLR, herein
referred to as FcRnull) (Horton et al., 2010). Despite equivalent
neutralizing activity in TZM-bl assays (Pietzsch et al., 2012),
FcRnull antibodies were far less potent than controls in vivo
(Figure 2 and Data S2). Mice treated with FcRnull tri-mix initially
suppressed viremia at the same rate as the wild-type antibody-
treated mice (Figure 2A). However, 9 of 15 mice receiving post-
exposure prophylaxis with the FcRnull tri-mix showed viral
rebound by 44 days after the last antibody injection. In
contrast, 44 days after the last injection of control antibodies,
only 1 of 21 mice showed rebound viremia (p = 0.0004). Not
only was the delay in viral rebound significantly reduced for
FcRnull antibodies, but the antibody levels at the time of viral
rebound were 50-fold higher for mice receiving FcRnull tri-
mix compared to wild-type tri-mix (p = 0.0007, Figure 2B).
This suggests that FcRnull antibodies have reduced activity
in vivo, and thus Fc function enhances antibody activity but is
not an absolute requirement.
The escape variants to the individual bNAbs in the tri-mix
used in these experiments have been documented extensively
(Horwitz et al., 2013; Klein et al., 2012b). However, we have
never observed HIV-1 escape by mutation to the bNAb tri-
mix. Rather, viral rebound is usually due to a drop in antibody
concentrations to subtherapeutic levels (Horwitz et al., 2013;
Klein et al., 2012b). Because mice receiving FcRnull tri-mix
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Figure 1. Postexposure Prophylaxis with bNAbs
(A) Schematic timeline for the bNAb (top) and ART (bottom) experiments.
(B) Plasma viremia for untreated mice. The x axis is days post HIV-1 challenge. The y axis is viral RNA copies/ml. Gray shading indicates values beneath the
detection limit of 800 copies/ml. The blue line indicates the geometric mean of plasma viremia.
(C) Plasma viremia for ART-treated mice. Graph as in (B). The blue shading indicates the treatment period with ART.
(D) Plasma viremia for antibody-treated mice. The red arrows indicate antibody tri-mix injections. The dashed red line shows average plasma antibody con-
centration (mg/ml) for all mice in the group.
(E) Graph as in (D) for mice treated with antibody starting 8 days after HIV-1 challenge.
(F) The proportion of mice that were aviremic at the terminal point for each treatment group (*p < 0.05; Fisher’s exact test).
(G) Percentage of CD4+ T cells in the spleen at the terminal point measured by flow cytometry, organized by treatment group. A, aviremic; V, viremic.
(H) Cell-associated HIV-1 RNA measured in spleen T cells at the terminal point, plotted as the ratio of HIV-1 RNA to CCR5 copies for each mouse. Gray shading
indicates the detection limit of 1.25 3 105 copies per cell.
(I) Cell-associated HIV-1 DNA measured in spleen T cells at the terminal point, plotted as the ratio of HIV-1 DNA to CCR5 copies for each mouse. Gray shading
indicates the detection limit of 2.0 3 105 copies per cell.
Mice that died prematurely are not included in Figures 1G–1I. See also Figures S1, S2, and Data S1.showed viral rebound in the presence of antibody concentra-
tions far higher than the therapeutic threshold for wild-type an-
tibodies (Figure 2B), we cloned and sequenced gp120 from the
9 mice that rebounded by day 44 to examine the mechanism for
viral breakthrough in the presence of FcRnull tri-mix (Figure 2C).
Among all 40 clones sequenced, not a single clone had the tri-
ple combination of signature mutations that confer escape tothe antibody-tri-mix. We conclude that viral rebound in FcRnull
tri-mix-treated mice is not attributable to antibody escape but,
rather, reduced antibody potency. Thus, FcRnull mutant anti-
bodies, which cannot engage Fc receptors, are less active in
suppressing infection than their wild-type counterparts, and
optimal postexposure prophylaxis by bNAbs requires engage-
ment of Fc receptors.Cell 158, 989–999, August 28, 2014 ª2014 Elsevier Inc. 991
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Figure 2. FcRnull Antibodies Suppress
Viremia but Do Not Prevent Rebound
(A) Plasma viremia as in Figure 1D for mice treated
with FcRnull tri-mix.
(B) For all viremic mice, plasma antibody con-
centration (mg/ml) on the day of viral rebound.
Antibody levels were significantly higher in FcRnull
tri-mix-treated mice compared to wild-type tri-
mix-treated mice (*p < 0.05; **p < 0.01; Mann-
Whitney U test).
(C) Sequences of gp120 cloned from plasma.
Horizontal lines denote individual clones, grouped
by mouse, shown on the right. Red ticks and green
ticks indicate nonsynonymous and synonymous
substitutions relative to gp120YU2, respectively.
Blue shading highlights sites of mutations that
confer escape to the antibody tri-mix.
See also Data S2.Combination Therapy with bNAbs and Inducers
A small number (15%) of chronically infected hu-mice and ma-
caques treated with antibodies fail to show rebound viremia after
therapy is discontinued (Barouch et al., 2013; Horwitz et al.,
2013; Klein et al., 2012a; Shingai et al., 2013). This suggests
that antibodies may be able to decrease the size of the reservoir
or interfere with its maintenance in established infections. To
determine whether agents that induce viral transcription from
latently infected cells can enhance this effect, we combined anti-
body therapy with viral inducers (Figure 3 and Data S3).
Hu-mice with established HIV-1YU2 infections (viremia ranging
from 4.70 3 103–7.96 3 105 copies/ml at 2–3 weeks after infec-
tion; Figures 3B–3E) were treated with tri-mix bNAbs. When
plasma viremia and cell-associated HIV RNA dropped below
detection, they were co-administered a viral inducer for 5–14
days and monitored for viral rebound for an additional 47–85
days (Figures 3B–3E and S3). The inducers tested were vorino-
stat, an HDAC inhibitor (Archin et al., 2009a; Archin et al.,
2009b; Contreras et al., 2009); I-BET151, a BET protein inhibitor
(Boehm et al., 2013b; Dawson et al., 2011); and CTLA, a T cell
inhibitory pathway blocker (Alegre et al., 2001; Krummel and Alli-
son, 1995). They were selected because of their documented
abilities to induce HIV-1 transcription in vitro, as well as their
safety and established pharmacokinetic properties in mice
(Krejsgaard et al., 2010;Kwonet al., 1997;Nicodemeet al., 2010).
Hu-mice receiving antibodies plus vorinostat showed no sig-
nificant differences in viral rebound compared to hu-mice
receiving antibody alone (Figures 3B and 3C and Data S3). The
same result was seen for hu-mice treated with antibodies plus
I-BET151 or CTLA (Figures 3D and 3E and Data S3). All 10992 Cell 158, 989–999, August 28, 2014 ª2014 Elsevier Inc.mice that received antibody therapy plus
vorinostat showed viral rebound when
the antibody dropped below therapeutic
levels. Of 12 mice that received antibody
therapy plus I-BET151, 11 had viral
rebound, and 10 of 11 mice that received
antibody plus CTLA showed viral
rebound. In total, of 33 mice that received
antibody plus a single inducer, 31 showedviral rebound. In comparison, of 25 mice that received antibody
therapy alone, 22 rebounded after the level of passively adminis-
tered antibody decayed below the therapeutic threshold (p =
0.64, Fisher’s exact test).
To determine whether a combination of inducers might be
more effective than a single inducer, we administered all three in-
ducers simultaneously (Figure 4 and Data S4). In the absence of
antibody therapy, the combination of all three inducers did not
alter the human graft and did not abort or noticeably alter active
infection (Figure S4). Additionally, the human graft did not differ
between groups of mice that received antibody alone versus
antibody plus the combination of inducers (Figure S4). 23 mice
that initially suppressed viremia on antibody therapy were
treated with the inducers combination and followed for 62–
105 days after the last antibody injection (Figure 4A). Only 10
of the 23 mice (43%) showed viral rebound, and the remaining
57% of mice failed to rebound, a significant decrease in rebound
frequency compared to antibody alone (p = 0.0018, Fisher’s
exact test) or to antibody plus a single inducer (p = 0.0001,
Fisher’s exact test) (Figures 4B and S5).
Importantly, when compared to antibody alone, neither single
inducers nor combination inducers measurably altered the fre-
quency of CD4+ T cells remaining at the end of the experiment
(Figure 5A). Additionally, cell-associated viral RNA measured in
splenic T cells at the terminal point supported the results from
the plasma viremia levels, with mice that failed to show viral
rebound in the plasma also having undetectable cell-associated
viral RNA (Figure 5B).
Finally, when compared to controls, hu-mice that failed to
rebound after combination antibody and inducer therapy
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Figure 3. Rebound Viremia after Therapy
with Single Inducers
(A) Schematic timeline of the experiment.
(B–D) Graphs show plasma viremia for individual
mice on the left y axis and geometric mean anti-
body level (mg/ml) on the right y axis among all mice
in the group (red). The x axis represents days
relative to the first antibody injection. Antibody in-
jections are indicated with red arrows. Mice that
had rebound plasma viremia are shown in gray.
Mice that failed to rebound are shown in black.
(B) Mice that received tri-mix antibodies but no
inducers.
(C) Mice that received tri-mix antibodies and vor-
inostat (green arrows).
(D) Mice that received tri-mix antibodies and
I-BET151 (purple shading).
(E) Mice that received tri-mix antibodies and CTLA
(orange arrows).
See also Data S3 and Figures S3 and S5.showed similar initial plasma viremias to mice that rebounded
across all experimental groups (Figure 5C). Therefore, neither
initial viremia levels nor CD4+ T cell levels can account for the dif-
ferences between the experimental groups.
To determine whether antibody persistence or premature
termination accounted for differing viral rebound outcomes, we
calculated antibody levels at the time of rebound and at the ter-
minal point for 59 of the 63 rebounding mice. The average
plasma antibody concentration at the time of viral rebound was
2.97 mg/ml (Figure 5D). Because the antibody concentrations de-
cayed to 2.97 mg/ml at different rates in individual mice, we
calculated the number of days that elapsed from when each in-
dividual mouse’s antibody levels reached 2.97 mg/ml to when the
mouse showed rebound viremia. Of 59 mice, 50 rebounded
within 10 days (Figure 5E). Of the 18 nonrebounding mice, the
average antibody concentration at the terminal point was
0.44 mg/ml, with 15 out of 18 mice having antibody concentra-
tions <2.97 mg/ml. Furthermore, in nonrebounding mice, an
average of 20.2 days elapsed from the time antibody concentra-
tions reached 2.97 mg/ml to termination (Figure 5F). Thus, failure
to rebound cannot be explained by antibody persistence or pre-
mature termination.
Finally, we could not detect viral DNA at the terminal point in
the majority of mice that did not rebound, whereas the majority
of mice that did rebound had detectable HIV-1 DNA, with anCell 158, 989–99average of 0.09 copies per T cell (Fig-
ure 5G). We conclude that combining
vorinostat, I-BET151, and CTLA with
immunotherapy decreases the frequency
of viral rebound in hu-mice.
DISCUSSION
Eliminating the HIV-1 reservoir in chronic
infection is essential to curing the disease,
but direct measurement of the latent
reservoir to evaluate therapeutic eradica-tion strategies remains difficult (Siliciano and Siliciano, 2013).
Quantitative viral outgrowth assays and PCR-based assays of
integrated DNA yield disparate results (Eriksson et al., 2013), in
part because PCR cannot distinguish between inactive and
permanently disabled proviruses, whereas outgrowth assays
underestimate reservoir size (Ho et al., 2013). Indeed, the best
way to determine whether a persistent reservoir exists is to mea-
sure viral rebound after discontinuing therapy in vivo.
Because the precise cellular andmolecular nature of the HIV-1
reservoir is debated, it is not possible to know with certainty how
its composition might differ between humans, macaques, and
hu-mice. Hu-mice resemble infected humans in that they contain
human cells that are infected with authentic HIV-1 (Brehm et al.,
2014; Hatziioannou and Evans, 2012). In addition, the kinetics of
viral rebound in hu-mice after suppression of viremia with ART
resembles infected humans (Horwitz et al., 2013; Nischang
et al., 2012). However, human hematopoietic reconstitution in
mice is incomplete; thus, important cellular elements of the
reservoir may be absent in hu-mice. Additionally, the human
graft and the infection can only be maintained in mice for a
limited time, making it impossible to distinguish between inte-
grated and unintegrated forms of HIV-1 latency (Bukrinsky
et al., 1991).
The macaque model is valuable because it represents an
immunologically intact host that may harbor reservoirs found in9, August 28, 2014 ª2014 Elsevier Inc. 993
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See also Data S4 and Figures S3, S4, and S5.humans, but not in mice. However, the infection in macaques in-
volves nonhuman primate cells with SHIV or SIV, which differ
significantly from HIV-1 molecularly and in their response to
drug therapy. Thus, neither of the two model systems is entirely
faithful to the human infection. Nevertheless, the two models
have produced very similar results in both immunotherapy and
prevention experiments to date (West et al., 2014). Whether
our results with inducers will translate to infected humans can
only be determined in clinical studies.
Despite the potential differences between available models,
our experiments indicate that bNAbs can interfere with the
establishment of the reservoir in humanized mice when ad-
ministered early in the infection. One of the key differences
between antibodies and ART is that antibodies can engage a
variety of host immune effector pathways by way of their Fc re-
ceptors (Nimmerjahn and Ravetch, 2008). Consistent with this
important difference, our experiments show that the mecha-
nism by which antibodies suppress active infection is depen-
dent on their ability to engage components of the immune
system by binding to Fc receptors. Engagement of these recep-
tors is also implicated in antibody-mediated protection against
infection in mice and macaques (Hessell et al., 2007; Pietzsch
et al., 2012). However, in contrast to the relatively modest effect
of FcR engagement on prophylaxis against initial infection (Hes-
sell et al., 2007; Pietzsch et al., 2012), the 50-fold effect on the
dose of antibody required to suppress viral rebound after early
therapy is impressive. One potential explanation for the differ-
ence in relative antibody potency for prevention versus sup-
pression of rebound viremia is that the effects on the latter
are compounded over a far longer period of antibody therapy
(McMichael et al., 2010).
One of the strategies proposed to eliminate latent viruses in-
volves inducing their expression under the cover of ART. In the-
ory, this would kill actively infected cells while preventing the
spread of infection (Deeks, 2012). In vitro experiments indicate
that silent proviruses can, in fact, be induced to become active
by a variety of different agents that impact viral transcription
(Bullen et al., 2014; Ho et al., 2013). However, whether reacti-
vated cells will die by the cytopathic effect in the presence of
ART has recently been called into question (Shan et al., 2012).
Of the three inducers that we tested, vorinostat is the only one994 Cell 158, 989–999, August 28, 2014 ª2014 Elsevier Inc.that has been studied in HIV-1-infected
humans for this purpose. Infected indi-
viduals treated with vorinostat plus ARTshowed a transient increase in resting CD4+ T cell-associated
HIV-1 RNA but no change in plasma viremia or in the frequency
of replication-competent HIV-1 within resting CD4+ T cells (Ar-
chin et al., 2014; Archin et al., 2012). Our results in hu-mice
are consistent with the human studies and extend them to addi-
tional candidate inducers, demonstrating that administration of
a single inducer has no significant effect on the ability of the
latent reservoir to produce rebound viremia. Although we could
not detect an increase in viremia following administration of
either single or combination inducers, antibodies were still pre-
sent and may have interfered with our ability to detect the virus
(Igarashi et al., 1999).
Antibody and inducer combinations have not been optimized,
and we cannot explain why 43% of mice receiving antibodies
plus combination inducers continue to rebound. Nor havewe ad-
dressed the mechanism that would explain the difference be-
tween single and combination inducers. However, experiments
using cell lines that contain artificial indicators of HIV-1 latency
indicate that HDAC and BET protein inhibitors show synergy
with transcriptional activators in reactivating HIV-1 in vitro
(Boehm et al., 2013a; Dar et al., 2014; Quivy et al., 2002; Reuse
et al., 2009). Consistent with the in vitro experiments, the combi-
nation of inducers appears to be synergistic in vivo because sin-
gle inducers had no measurable effect above the background
controls, whereas 57% of the hu-mice treated with antibodies
plus combination inducers failed to rebound. Irrespective of the
mechanism, the reduction in viral rebound suggests that the
reservoir of HIV-1-infected cells remaining after combination
inducer and antibody therapy in hu-mice is significantly
decreased, establishing the principle that the HIV-1 reservoir
can be altered by combination therapy with antibodies and in-
ducers in vivo.
EXPERIMENTAL PROCEDURES
Mice
NOD Rag1/Il2rgNULL (NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ, NRG) mice were
purchased from The Jackson Laboratory. All mice were bred and maintained
at the Comparative Bioscience Center of The Rockefeller University according
to guidelines established by the Institutional Animal Committee. All experi-
ments were performed with authorization from the Institutional Review Board
and the IACUC at The Rockefeller University.
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Figure 5. Antibody Persistence and Premature Termination Do Not Account for Nonrebounding
(A) Percentage of CD4+ T cells at the terminal point measured in the spleen by flow cytometry, organized by treatment group and rebound status (N.R., non-
rebounder; Reb., viral rebounder).
(B) Cell-associated HIV-1 RNA measured in spleen cells at terminal point, plotted as the ratio of HIV-1 RNA to CCR5 DNA copies for each mouse. Mice that had
measureable HIV-1 RNA but undetectable CCR5 DNA are plotted as 104 copies per cell.
(C) Plasma viremia before therapy was initiated for each mouse. There was no significant difference for any individual group (Kruskal-Wallis test).
(D) The plasma antibody level (mg/ml) at the time of viral rebound for each mouse that rebounded, organized by treatment group. Themean plasma antibody level
at the time of rebound was 2.97 mg/ml for all groups.
(E) For each mouse that rebounded, the number of days that elapsed from when the antibody level dropped below 2.97 mg/ml to the time of rebound.
(F) For mice that did not rebound, the number of days that elapsed from when each mouse’s antibody levels dropped below 2.97 mg/ml to the terminal point.
(G) Cell-associated HIV-1 DNA measured in spleen T cells at the terminal point, plotted as the ratio of HIV-1 DNA to CCR5 copies for each mouse. Mice that had
measureable HIV-1 DNA but undetectable CCR5 DNA are plotted as 104 copies per cell.
Mice that died prematurely are not included in Figures 5A, 5B, and 5G.Humanized Mice
Humanized mice were generated as previously described (Klein et al., 2012b).
In brief, human fetal livers were obtained from Advanced Bioscience Re-
sources (ABR). Fetal livers were homogenized and incubated in HBSS media
with 0.1% collagenase IV (Sigma-Aldrich), 40 mM HEPES, 2 mM CaCl2, and
2 U ml1 DNAase I (Roche) for 30 min at 37C. Hematopoietic stem cells
(HSCs) were isolated from digested liver using CD34+ HSC isolation kit
(Stem Cell Technologies). Neonatal NRG mice (1–5 days old) were sublethally
irradiated with 100 cG and injected intrahepatically with 23 105 human CD34+
HSCs 6 hr after irradiation.
Mouse Screening for Humanization
Eight or more weeks after HSC injection, mice were screened for the presence
of human lymphocytes in peripheral blood by flow cytometry. 200 ml wholeblood was collected by facial vein bleed and peripheral blood mononuclear
cells (PBMCs) were isolated by density gradient centrifugation using Ficoll-Pa-
que Plus (GE Healthcare Life Sciences). PBMCs were stained with antibodies
to mouse CD45-PECy7, human CD45-Pacific Orange, human CD3-Pacific
Blue, human CD19-APC, human CD4-PE, human CD8-FITC, and human
CD16-Alexa700 for 25 min at 4C. Cells were washed and fixed using Cyto-
fix/Cytoperm (BD Biosciences). Flow cytometry analysis was performed with
a LSRFortessa (BD) and FlowJo software (Tree Star). For eachmouse, the per-
centage of human lymphocytes ([100 3 human CD45+] / [human CD45+ +
mouse CD45+]), termed huCD45+ %, and the percentage of human CD4+
T cells (100 3 human CD45+CD3+CD4+ / human CD45+), termed huCD4+ %,
was calculated. Mice with at least 10% huCD45+ and 10% huCD4+ were
selected for postexposure prophylaxis experiments and were infected with
two doses of HIV-1YU2 (150 ng p24) by i.p. injections, 24 hr apart. PretreatmentCell 158, 989–999, August 28, 2014 ª2014 Elsevier Inc. 995
viremia was measured at 72–96 hr following the first HIV-1YU2 injection, and
treatment was initiated 4 days following the first injection. For experiments
assessing the effects of bNAbs and inducers on established infections, mice
with measurable human CD4+ cells by FACS were injected with two doses
of HIV-1YU2 (150 ng p24), and pre-treatment viremia was measured 14–
20 days after the first injection. Mice with plasma viral loads >3,000 RNA
copies/ml were selected to receive antibody therapy. After five subcutaneous
antibody injections (see below), posttreatment viremias were measured. Only
mice with completely suppressed plasma viremias were selected for further
analysis and to receive viral inducers.
Plasma Viral Load Measurements
300–500 ml of whole blood was collected frommice at each time point by facial
vein bleed. Whole blood was spun at 300 3 g for 10 min to separate plasma
from the cellular fraction. Total RNA was extracted from 100 ml plasma using
QIAmp MinElute Virus Spin Kit (QIAGEN) in combination with RNase-free
DNase (QIAGEN), eluted in a 50 ml volume. HIV-1 RNA was quantified by
qRT-PCR. The reaction mixture was prepared using TaqMan RNA-to-Ct
1-Step kit (Applied Biosystems), with 20 ml of eluted RNA, and a sequence
specific probe targeting a conserved region of the HIV-1 pol gene (/HEX/50-
CCCACCAACARGCRGCCTTAACTG-30/ZenDQ, HXB2 nt 4603 to 4626) (Inte-
grated DNA Technologies). Forward and reverse primer sequences were
50-TAATGGCAGCAATTTCACCA-30 (HXB2 nt 4577-4596) and 50-GAATGCCA
AATTCCTGCTTGA-30 (HXB2 nt 4633 to 4653), respectively. Cycle threshold
(Ct) valueswere calibrated using standard sampleswith known amounts of ab-
solute viral RNA copies. The quantitation limit was previously determined to be
800 copies/ml (Klein et al., 2012b).
Gp120 Sequencing
Gp120 cloning and sequencing was performed as previously described (Klein
et al., 2012a). In brief, cDNAwas synthesized from viral RNA using SuperScript
III reverse transcriptase (Invitrogen Life Technologies). cDNA was amplified
with Expand Long Template PCR System (Roche) with nested PCR. Primers
for the first round of PCR were 50-GGCTTAGGCATCTCCTATGGCAGGAA
GAA-30 and 50-GGTGTGTAGTTCTGCCAATCAGGGAAGWAGCCTTGTG-30.
Primers for the second round of PCR were 50-TAGAAAGAGCAGAAGACA
GTGGCAATGA-30 and 50-TCATCAATGGTGGTGATGATGATGTTTTTCTCTC
TGCACCACTCTTCT-30. Gel-purified PCR amplicons were ligated into
pCR4-TOPO (Invitrogen) and transformed into One Shot TOP10 cells. Individ-
ual colonies were sequenced usingM13F andM13R primers. Sequences were
aligned to gp120YU2 (accession number M93258) and analyzed for mutations
using Los Alamos Highlighter tool (http://www.hiv.lanl.gov/content/sequence/
HIGHLIGHT/HIGHLIGHT_XYPLOT/highlighter.html).
Cell-Associated HIV-1 RNA
The cellular fraction of whole blood was resuspended in 400 ml PBS, and
PBMCs were isolated by density gradient centrifugation as described above.
Lymphocytes were split into two samples, one for cell-associated HIV-1 RNA
measurements and one for cell-associated HIV-1 DNA measurements. Cell-
associated RNA was extracted and quantified by the same procedures as
described above for plasma viral RNA. The lower limit of detection was deter-
mined to be ten copies of viral RNA per qRT-PCR reaction. Cell-associated
HIV-1 RNA is reported as the ratio of HIV-1 RNA copies per sample to CCR5
genomic DNA copies per equivalent sample measured in DNA extract. For ter-
minal point measurements, spleen tissue was isolated, homogenized, and
filtered through 40 mm mesh. Splenocytes were used to isolate HIV-1 RNA
as described above.
Cell-Associated HIV-1 DNA
PBMCs were isolated from whole blood as described above. Splenocytes
were isolated from spleen as described above. Total DNA was extracted using
QIAmp DNA Blood Mini Kit (QIAGEN) and eluted in 80 ml volume. Purified DNA
was quantified for HIV-1 DNA by qPCR using the primers and probe for HIV-1
RNA quantification mentioned above. Genomic human CCR5 DNA was quan-
tified with primers 50-GTTGGACCAAGCTATGCAGGT-30 (forward) and 50-
AGAAGCGTTTGGCAATGTGC-30 (reverse) and the sequence-specific probe
/HEX/50-TTGGGATGACGCACTGCTGCATCAACCCCA-30/ZenDQ. All qPCR996 Cell 158, 989–999, August 28, 2014 ª2014 Elsevier Inc.reactions contained 25 ml AmpliTaq Gold PCR master mix (Applied Bio-
systems) in 50 ml reaction volume. Reaction mixtures were as previously
described (Horwitz et al., 2013). HIV-1 DNA is reported as copies per sample
to CCR5 genomic copies per equivalent sample.
Terminal Graft
The presence of human lymphocytes at the terminal point was quantified from
the spleen and PBMCs by flow cytometry. Isolation of PBMCs and splenocytes
were as described above. Staining procedures were as described above.
Antibody Concentrations
Plasma levels of passively administered antibodies were quantified by two in-
dependent methods. gp120-specific ELISAwas as previously described (Klein
et al., 2012b), using 10-1074 and 3BNC117 monoclonal antibodies as stan-
dard controls. The detection limit was 0.05 mg/ml. Because PG16 does not
bind gp120 and endogenously produced gp120-reactive antibodies could
confound the ELISA measurement, plasma antibody levels were also quanti-
fied by TZM-bl neutralization using the Tier 2 envelopes 3301.v1.c24 and
YU2. A mixture with known amounts of 3BNC117, 10-1074, and PG16 was
used as standard for calibration.
Day of Viral Rebound and Antibody Level at Rebound
Plasma viremias immediately preceding and following viral rebound were
plotted on a semi-log-y axis versus days postinitial antibody injection (x axis)
for each individual mouse. The linear portion of viremia was fit to a line by
least-squares linear regression. The day that viremia crossed the 800
copies/ml quantitation limit, termed rebound day, was calculated from the
viremia fit. The antibody concentrations (as determined by TZM-bl neutraliza-
tion) spanning before and after viral rebound were plotted on a semi-log-y axis
versus days postinitial antibody injection. The linear portion of antibody con-
centrationswas fit to a line by least-squares linear regression, and the antibody
concentration on the rebound day was calculated from the fit.
Antiretroviral Therapy
Individual tablets of tenofovir disproxil-fumarate (TDF; Gilead Sciences), emtri-
citabine (FTC; Gilead Sciences), and raltegravir (RAL; Merck) were crushed
into fine powder andmanufactured with TestDiet 5B1Q feed (Modified LabDiet
5058 with 0.12% amoxicillin) into 1/2’’ irradiated pellets. Final concentrations
of ART drugs in the food were 720 mg/kg TFV, 520 mg/kg FTC, and
4800 mg/kg RAL. Doses were chosen based on suppression of viremia in hu-
manized mice as previously published (Denton et al., 2012; Nischang et al.,
2012) and by pharmacokinetic analysis of these drugs in humanized mice
(Roberto F. Speck, personal communication). To test potential toxicity or
reduced preference for drug-supplemented food, mice were weighed daily
on normal diet and then switched to ART feed and weighed daily. There
were no visible signs of toxicity, and mice maintained their weights. Assuming
that mice weigh 25 g and eat 4 g of food per day, the drug doses correspond to
2.88 mg/kg TFV, 83 mg/kg FTC, and 768 mg/kg RAL daily.
Antibody Therapy
Plasmids encoding 10-1074 or PG16 heavy- and light-chain Ig genes were
transfected into HEK293E cells. Antibodies were isolated from tissue-culture
supernatant using Protein G Sepharose 4 Fast-Flow (GE Healthcare). Anti-
bodies were then buffer exchanged into PBS and sterile filtered using Ultra-
free-CL centrifugal filters (0.22 mm; Millipore). Endotoxin was removed from
antibody preparations using Triton X-114 (Sigma-Aldrich) as previously
described (Aida and Pabst, 1990), and antibodies were concentrated to
10mg/ml. Sterile, endotoxin-free 3BNC117 (20mg/ml) was obtained fromCell-
Dex Therapeutics. All antibodies were injected subcutaneously as described.
Inducers
Vorinostat (Selleckchem) was suspended in sterile water or sterile water plus
0.5% methylcellulose, 0.1% Tween (v/v) and administered by oral gavage at
doses of 60 mg/kg (Krejsgaard et al., 2010). For each mouse, three total doses
were administered, spaced 48 hr apart. 100 mg doses of aCTLA4 were injected
intraperitoneally (i.p.). Three total doses were administered, spaced 48 hr
apart. I-BET 151 was obtained from GlaxoSmithKline and dissolved in 10%
beta-cyclodextrin, 5% DMSO in 0.9% saline and injected daily for 14 days at
doses of 30 mg/kg (Dawson et al., 2011).
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 6.0 for Mac OS X.
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